Peripheral Neuropathy Trial, Recruiting NCT06845644 Sponsor: Assistance Publique Hopitaux De Marseille Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06845644
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years old
  • People who have freely agreed to take part in the study
  • People who have been diagnosed with hereditary CMT neuropathy (a nerve condition confirmed through genetic testing)
  • People who have been diagnosed with an acquired demyelinating neuropathy, such as typical CIDP or anti-MAG neuropathy in its typical form (nerve conditions where the protective covering of nerves is damaged)
  • People who have a confirmed genetic mutation in the transthyretin (TTR) gene, which is linked to a hereditary nerve condition
  • People who are enrolled in or entitled to benefits under a French social security scheme

Who may not be able to join:

  • People who have another peripheral nerve condition, either currently or in their medical history
  • People with a history of alcohol or psychoactive substance misuse
  • People who cannot have an MRI scan for any of the following reasons: claustrophobia (fear of enclosed spaces), having a pacemaker, a Holter monitoring device, an IUD (contraceptive coil), metal surgical clips, metal prostheses or implants, or any other metal objects in the body
  • People whose disability is too severe to allow them to undergo an MRI scan
  • People who are currently participating in another research study that restricts them from joining additional trials
  • People in certain protected groups under French law, including minors, adults under legal guardianship, people who are detained, and women who are pregnant or breastfeeding
  • People who are not able to read and understand French well enough to provide informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: François CREMIEUX, Assistance Publique - Hôpitaux de Marseille

Phone: 04 91 38 65 79

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 May 2025
Est. completion
23 May 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Annual intramuscular fat fraction progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov